Novo Nordisk launches Wegovy pill in the US with a starting price of US$149 to intensify competition

Danish pharmaceutical company Novo Nordisk has started marketing its weight loss pill, Wegovy, in the Estados Unidos market, setting a new level in the competition for obesity treatments. The oral version of the drug, which simulates the hormone GLP-1 to control appetite, comes with an initial cost substantially lower than injectable alternatives, seeking to expand access to millions of patients.
Approval by the US regulatory agency, granted shortly before the end of last year, allowed the company to introduce a more convenient, needle-free option. The initiative is a direct response to the growing demand for effective weight management solutions and aims to solidify Novo Nordisk’s position in a rapidly expanding and highly competitive pharmaceutical sector.
With this launch, the company seeks to reach a significant portion of the more than 100 million North Americans who live with obesity, offering an alternative that combines proven effectiveness with greater ease of use on a daily basis. The pricing and distribution strategy was designed to maximize product penetration in a short space of time.
A new era in obesity treatment
The introduction of the Wegovy pill represents a significant advance, being the first and only oral medication that mimics the hormone GLP-1, essential in regulating appetite and promoting satiety. Diferente of injectable therapies, which require subcutaneous application, the daily tablet version eliminates an important barrier for many patients who experience discomfort with needles, which can increase adherence to long-term treatment. The mechanism of action focuses on delaying gastric emptying and acting on brain receptors that control hunger, resulting in lower caloric intake. Estudos clinicians who supported its approval demonstrated an average weight loss of approximately 17% in participants, consolidating the pill as a powerful and transformative tool in the clinical management of obesity, alongside diet and physical exercise.
Aggressive pricing strategy to expand access
The pricing policy adopted by Novo Nordisk for oral Wegovy has been carefully calibrated to appeal to a broad spectrum of consumers. For Para patients who bear the full cost of treatment, the initial dose of 1.5mg was set at US$149 per month, equivalent to around US$5 per day.
This value is considerably lower than the expectations of many market analysts and positions the drug competitively compared to other therapies.
For the 4mg dose, the company established a promotional price of US$149 per month, valid until April 15, when the value will be readjusted to US$199 per month.
Higher dosages, which represent the maintenance phase of treatment for many users, will have a fixed cost of US$299 per month. Pacientes with health insurance coverage can access the medication for even lower prices, starting at US$25 per month, depending on the plan.
The fierce competition with Eli Lilly in the market
The launch of the Wegovy pill intensifies direct competition with Eli Lilly, its main competitor in the obesity medication segment. Eli Lilly has in its portfolio the successful injectables Mounjaro and Zepbound, which also act on hormonal pathways to promote weight loss and have gained a significant share of the market. The arrival of a more affordable, oral alternative from Novo Nordisk is a strategic move to challenge the rival’s dominance and attract patients seeking more convenience or who are not covered by insurance to the injectable versions, which can cost more than $1,000 per month.
The financial market’s response was immediate, with Novo Nordisk shares rising after the announcement, although the company has faced devaluation in the last year due to strong competition. Ambas pharmaceutical giants are in a real price war, adjusting the costs of their treatments for uninsured patients and investing heavily in marketing. Analistas from the sector, like Matt Weston from UBS, highlighted that the price of the Novo Nordisk pill was lower than expected, signaling an aggressive tactic to quickly gain market share and put pressure on Eli Lilly, which is still developing its own oral version of an anti-obesity drug.
How the Wegovy pill works
The daily formulation of oral Wegovy acts as a glucagon-like peptide-1 (GLP-1) receptor agonist. By imitating the action of this intestinal hormone, the medicine signals a feeling of satiety to the brain, reducing hunger and, consequently, the amount of food consumed by the patient. Essa direct action on the appetite regulation system is what leads to the sustained weight loss observed in clinical studies.
Wide availability in pharmacies and telemedicine
To ensure that the medicine reaches as many patients as possible, Novo Nordisk has established a vast distribution network in the Estados Unidos. The Wegovy pill is now available in more than 70 thousand pharmacies across the country.
Among the points of sale are large retail chains such as CVS and Costco, which have wide reach and facilitate access for consumers in different regions.
In addition to physical pharmacies, the company has also entered into partnerships with important telemedicine providers, including platforms such as Ro, LifeMD and Weight Watchers. Essa integration with digital health services allows patients to obtain prescriptions and medical follow-up remotely, increasing convenience and removing geographic barriers to initiating treatment.
Prospects for global expansion of the drug
With the successful launch in the Estados Unidos, Novo Nordisk now turns its attention to the global expansion of the Wegovy pill. The next crucial step is approval in other important regulatory markets, such as Europe.
The Reino Unido regulatory agency is already evaluating the drug, and a decision is expected later this year. Approval in the UK market could open the door to rapid dissemination throughout Europa, where the prevalence of obesity also represents a major public health challenge and a significant potential market for the pharmaceutical company.







